Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 12/05/22
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid TumorsGlobeNewsWire • 11/15/22
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022GlobeNewsWire • 09/12/22
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor CellsGlobeNewsWire • 08/29/22
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical TrialGlobeNewsWire • 08/24/22
Enlivex Announces Second Quarter 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/22/22
Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid TumorsGlobeNewsWire • 08/17/22
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™GlobeNewsWire • 08/03/22
Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid CancersGlobeNewsWire • 07/06/22
Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 MeetingGlobeNewsWire • 05/09/22
Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with AllocetraGlobeNewsWire • 05/05/22
Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business UpdatesGlobeNewsWire • 04/29/22
Enlivex CSO Prof. Dror Mevorach Publishes Foundational Paper on the Pfizer–BioNTech COVID-19 Vaccine in The New England Journal of MedicineGlobeNewsWire • 10/12/21
Enlivex Therapeutics (ENLV) Sees Hammer Chart Pattern: Time to Buy?Zacks Investment Research • 09/27/21
Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDSGlobeNewsWire • 09/22/21
Enlivex to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/09/21
Here's Why Enlivex Therapeutics Ltd. (ENLV) is a Great Momentum Stock to BuyZacks Investment Research • 09/03/21